关注
Lei Shi
Lei Shi
MGH - Havard Medical School
在 mgh.harvard.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Acetyl-CoA and the regulation of metabolism: mechanisms and consequences
L Shi, BP Tu
Current opinion in cell biology 33, 125-131, 2015
7722015
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
2962019
Acetyl-CoA induces transcription of the key G1 cyclin CLN3 to promote entry into the cell division cycle in Saccharomyces cerevisiae
L Shi, B Tu
PNAS 110 (18), 7318-7323, 2013
1532013
Trehalose is a key determinant of the quiescent metabolic state that fuels cell cycle progression upon return to growth
L Shi, BM Sutter, X Ye, BP Tu
Molecular biology of the cell 21 (12), 1982-1990, 2010
1532010
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma
SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ...
Cancer discovery 6 (7), 727-739, 2016
1502016
Cycloheximide can distort measurements of mRNA levels and translation efficiency
DA Santos, L Shi, BP Tu, JS Weissman
Nucleic acids research 47 (10), 4974-4985, 2019
832019
Mutant IDH inhibits IFNγ–TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma
MJ Wu, L Shi, J Dubrot, J Merritt, V Vijay, TY Wei, E Kessler, KE Olander, ...
Cancer discovery 12 (3), 812-835, 2022
732022
Cycling transcriptional networks optimize energy utilization on a genome scale
GZ Wang, SL Hickey, L Shi, HC Huang, P Nakashe, N Koike, BP Tu, ...
Cell reports 13 (9), 1868-1880, 2015
632015
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ...
Cancer discovery 11 (10), 2488-2505, 2021
582021
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
T Weiss-Sadan, M Ge, M Hayashi, M Gohar, CH Yao, A de Groot, S Harry, ...
Cell metabolism 35 (3), 487-503. e7, 2023
492023
Npr2 inhibits TORC1 to prevent inappropriate utilization of glutamine for biosynthesis of nitrogen-containing metabolites
S Laxman, BM Sutter, L Shi, BP Tu
Science signaling 7 (356), ra120-ra120, 2014
492014
Protein acetylation as a means to regulate protein function in tune with metabolic state
L Shi, B Tu
Biochemical Society Transactions 42 (4), 1037-1042, 2014
492014
Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway
J Zhang, CM Simpson, J Berner, HB Chong, J Fang, Z Ordulu, ...
Cell 186 (11), 2361-2379. e25, 2023
482023
EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma
Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil, J Merritt, R Egan, MJ Wu, ...
Cancer discovery 12 (5), 1378-1395, 2022
462022
Biology of IDH mutant cholangiocarcinoma
MJ Wu, L Shi, J Merritt, AX Zhu, N Bardeesy
Hepatology 75 (5), 1322-1337, 2022
322022
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016; 6: 727–739. doi: 10.1158/2159-8290
SK Saha, JD Gordan, BP Kleinstiver, P Vu, MS Najem, JC Yeo, L Shi, ...
CD-15-1442.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
25
GATOR1 regulates nitrogenic cataplerotic reactions of the mitochondrial TCA cycle
J Chen, BM Sutter, L Shi, BP Tu
Nature chemical biology 13 (11), 1179-1186, 2017
212017
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers
L Shi, W Shen, MI Davis, K Kong, P Vu, SK Saha, R Adil, J Kreuzer, ...
Nature cancer 4 (3), 365-381, 2023
82023
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
M Takahashi, HB Chong, S Zhang, TY Yang, MJ Lazarov, S Harry, ...
Cell 187 (10), 2536-2556. e30, 2024
62024
EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2022; 12 (5): 1378–1395. doi: 10.1158 …
Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil
CD-21-1168, 0
6
系统目前无法执行此操作,请稍后再试。
文章 1–20